NICE rejects adjuvant use of Perjeta post-surgery

15th June 2018 Uncategorised 0

The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.

More: NICE rejects adjuvant use of Perjeta post-surgery
Source: News